Pituitary adenomas are benign intracranial neoplasms that are frequently well-controlled
with standard treatments that include surgical resection, radiotherapy, and agents that …

Background Treatment of aggressive pituitary adenomas typically involves a multimodality
approach based on histopathological features and may include pharmacotherapy, surgery …

Pituitary tumors are the most frequent intracranial tumor and classically considered as
benign. However, clinical evidence and recent advances in pathological and molecular …

Temozolomide is effective in some patients with progressive pituitary adenoma or
carcinoma. We report a survey study of Italian patients treated with Temozolomide because …

A small subset of pituitary adenomas grows despite maximal treatment with standard
therapies; namely, surgery and radiotherapy. These aggressive tumors demonstrate 2 …

OBJECTIVE: The management of aggressive pituitary macroadenomas represents a
challenge to neurosurgeons. These tumors are very difficult to treat, owing mainly to their …

Temozolomide is an alkylating chemotherapeutic agent used in malignant neuroendocrine
neoplasia, melanoma, brain metastases and an essential component of adjuvant therapy in …

Objective The prognosis of either pituitary carcinoma or aggressive pituitary adenoma
resistant to standard therapies is poor. We assessed the efficacy of treatment with …

We evaluated results of temozolomide (TMZ) therapy in six patients, aged 34–78 years,
presenting aggressive pituitary tumors. In all the patients tested O6‐methylguanine‐DNA …

Temozolomide (TMZ) has been shown as an effective treatment option in aggressive
pituitary adenomas and carcinomas. This review analyses the published case series and …